The table below shows Elicio Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$36.95M
-$37.07M
-$32.69M
-$22.18M
-$52.64M
-$22.89M
Capital expenditure
$16.00K
$87.00K
$66.00K
$654.00K
$382.00K
$41.00K
Investing cash flow
-$16.00K
-$84.00K
-$32.00K
-$654.00K
-$382.00K
-$41.00K
Dividends paid
-
-
-
-
ELTX operating cash flow (10-K history)
Elicio Therapeutics, Inc. reported operating cash flow of -$36.95M for fiscal year 2025. That is up 0.3% from -$37.07M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$22.89M (FY 2020) to -$36.95M. Figures come from the company's audited annual reports as filed with the SEC.